Storm Raises $56m To Take RNA Modification Inhibitor Into Phase II
STC-15 is a potential first-in-class small molecule targeting RNA-modifying enzymes with interim results in sarcoma expected later this year.
Scrip - April 16, 2026

Diamyd Down In The Dumps After Diabetes Drug Fail
The Swedish biotech has discontinued the Phase III DIAGNODE-3 trial of retogatein after an evaluation of an interim analysis confirmed futility; and a strategic review is underway.
Scrip - April 16, 2026

Executives On The Move: Ailux Gets A New CSO From AstraZeneca
Recent changes in the industry include board appointments at Avalyn Pharma, Faron Pharmaceuticals and Telix Pharmaceuticals, plus a raft of new appointments at Ambrose Healthcare include a new chief of intellectual property from GSK.
Scrip - April 16, 2026

Pharma Gains A Seat At The AI Table As Anthropic Taps Novartis’s Narasimhan
Fresh after acquiring a biotech company, AI firm Anthropic has added Novartis CEO Vas Narasimhan to its board of directors.
Scrip - April 16, 2026

D&D Pharmatech Raises $154m To Progress MASH, Core Assets
South Korean biotech’s successful funding buoyed by strong global investor interest and encouraging Phase II data for MASH contender DD01.
Scrip - April 16, 2026

Prolonged US Blockade Of Iran Ports Risks Drug Shortages, Wider Supply Chain Woes
A prolonged US blockade of Iranian ports might cause a supply chain impact so far restricted to Asia to spread wider in the mid-term. Experts believe generic drug shortages could result from portfolio restructuring, though innovator drugs remain largely insulated for now.
Scrip - April 16, 2026

Avanos CEO Says AIP Deal Strengthens Company’s Competitive Position
American Industrial Partners agreed to buy Avanos Medical in a deal worth about $1.27bn, which will gain it access to its flagship product Coolief . The deal marks the end of Avanos as a public entity.
Medtech Insight - April 16, 2026

Execs On The Move: April 6–10, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 16, 2026

People On The Move: Appointments At Haleon, Clasado, CK Life Sciences
A round-up of the latest consumer health people moves: Haleon names global transformation head; Clasado appoints APAC director; CK Life Sciences hires Vitaquest CEO.
HBW Insight - April 16, 2026

UK Oxybenzone Limits Take Effect July 2026
Marketers selling products containing oxybenzone in the UK must adhere to new concentration limits following amendments to the UK’s cosmetics framework.
HBW Insight - April 16, 2026

Henlius Targets One Of Oncology’s Toughest Biosimilars
Henlius has secured China IND clearance for HLX05-N, a proposed Erbitux (cetuximab) biosimilar, setting up a global Phase I trial and reigniting a long-stalled field where scientific complexity has kept rivals at bay despite blockbuster sales.
Generics Bulletin - April 16, 2026

Apotex Snatches First FDA Generic Approval For Sandoz’s Multivitamin Injection
Apotex said the approval of the generic vitamin combination injectable reflects the strong collaboration model it has with its partners Orbicular and Gland Pharma.
Generics Bulletin - April 16, 2026

Towa Targets Supply Resilience With Networked Manufacturing Shift
Japan’s Towa has signed a basic agreement with Adragos Pharma Kawagoe to expand manufacturing capacity, using outsourcing, parallel production and cross-company collaboration to stabilize supply of off-patent medicines and support broader industry reform.
Generics Bulletin - April 16, 2026

Sandoz Builds New Model For African Drug Access
Sandoz has signed a direct supply and manufacturing agreement with Rwanda to deliver around 60 essential medicines, positioning the country as a regional access hub while linking European antibiotic production capacity to growing demand across African markets.
Generics Bulletin - April 16, 2026

Healthtech Start-Ups Set The Tone At BioWales ’26
A “venture builder” in precision mental health biology, a company that has done the heavy lifting for a class III cardiac implantable and a diagnostics innovator addressing care shift realities long before the NHS’s 10-Year Plan was issued were among the start-ups seeking investors at BioWales 2026.
In Vivo - April 15, 2026

How An Italian Ocular AAV Innovator Is Bucking The Trend In Gene Therapy
AAVantgarde is advancing dual-AAV gene therapies for two inherited retinal diseases, using staged clinical de-risking to build investor and regulatory confidence ahead of key 2026 data readouts.
In Vivo - April 15, 2026

Rising Leaders: Helping AI Software Enter Healthcare Systems And Markets
Isabel Vincent, market development manager at life sciences software consultancy Firefinch, has seen an explosion in workload as healthcare organizations and healthtech innovators embed new functionalities into businesses processes. Away from that job, she finds time to advise and mentor start-ups.
In Vivo - April 15, 2026